Brenda Hashem
Primary Care · Berkeley Springs, WVNPI 1073983813
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 454 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$718
- Bayer$559
- Novo Nordisk$519
- Abbott$494
- Lilly USA, LLC$460
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,072100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,549 |
| Amgen | 39 | $718 |
| Bayer | 30 | $559 |
| Novo Nordisk | 29 | $519 |
| Abbott | 31 | $494 |
| Lilly USA, LLC | 30 | $460 |
| AstraZeneca | 20 | $447 |
| Phathom Pharmaceuticals, Inc. | 21 | $429 |
| Astellas Pharma US Inc | 20 | $419 |
| GSK | 16 | $277 |
| Corcept Therapeutics | 8 | $222 |
| Sanofi-aventis U.S. LLC | 12 | $200 |
| Merck | 10 | $200 |
| E.r. Squibb & Sons, L.L.C. | 12 | $188 |
| Pfizer | 9 | $164 |
| Otsuka America Pharmaceutical, Inc. | 10 | $163 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $121 |
| Eisai Inc. | 3 | $109 |
| Axsome Therapeutics, Inc. | 5 | $89 |
| Boehringer Ingelheim | 4 | $87 |
| Johnson & Johnson | 4 | $72 |
| Collegium Pharmaceutical, Inc. | 4 | $69 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $52 |
| Mylan Specialty L.p. | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Medtronic | 1 | $29 |
| Novartis | 2 | $28 |
| Viatris Specialty LLC | 1 | $24 |
| Vertex | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $16 |
| Insulet Corporation | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$124
How this compares
$8,081 in reported general payments places this provider in the 95th percentile of 43 primary care providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $80,260 |
| OzempicSemaglutide | 45 | $46,216 |
| XareltoRivaroxaban | 41 | $40,534 |
| JardianceEmpagliflozin | 28 | $37,131 |
| MounjaroTirzepatide | 37 | $36,857 |
| TrulicityDulaglutide | 23 | $27,434 |
| TivicayDolutegravir Sodium | 12 | $26,652 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $24,634 |
| JanuviaSitagliptin Phosphate | 25 | $23,677 |
| TradjentaLinagliptin | 13 | $19,699 |
| Spiriva HandihalerTiotropium Bromide | 11 | $15,677 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $15,608 |
| FarxigaDapagliflozin Propanediol | 22 | $15,537 |
| LinzessLinaclotide | 12 | $10,227 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $7,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $80,26073 claims |
| Lilly USA, LLCMounjaro, Trulicity | $460 | $64,29160 claims |
| Boehringer IngelheimJardiance, Tradjenta | $87 | $56,83041 claims |
| Novo NordiskOzempic | $519 | $46,21645 claims |
| Johnson & JohnsonXarelto | $72 | $40,53441 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $277 | $40,24133 claims |
| MerckJanuvia | $200 | $23,67725 claims |
| AstraZenecaFarxiga | $447 | $15,53722 claims |
| AbbVieLinzess, Synthroid | $1,549 | $12,83467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 primary care providers in West Virginia.
Other primary care in Berkeley Springs
- Amanda WakimWheeling$169K
- Brenda DennisGlen Dale$6K
- Molly WhiteCharleston$5K
- Richard SutherlandMartinsburg$4K
- Kayla MeadeHuntington$3K
- Crystal Clark-CrookshanksSummersville$3K
- Jessica FrankeGlen Dale$2K
- Jerica BoboRomney$2K
- Alisa EllisonHinton$2K
- Amber BellMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.